البحث عن طبيب

Keith C. Bible, M.D., Ph.D.

  1. Oncologist
طلب موعد

المنشورات

  1. Lee KK, Morris JC 3rd, Kumar A, Chintakuntlawar AV, Peskey C, Hilger CR, Bible KC, Ryder M. Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers. Head Neck. 2024 Oct 27 [Epub ahead of print]
    View PubMed
  2. Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol. 2023 Feb; 24 (2):175-186 Epub 2023 Jan 18
    View PubMed
  3. Shonka DC Jr, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH, Bible KC, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, Faquin WC, Ghossein RA, Gopal RK, Miyauchi A, Nikiforov YE, Ringel MD, Robinson B, Ryder MM, Sherman EJ, Sadow PM, Shin JJ, Stack BC Jr, Tuttle RM, Wirth LJ, Zafereo ME Jr, Randolph GW. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Jun; 44 (6):1277-1300 Epub 2022 Mar 11
    View PubMed
  4. Hassan Nelson L, Fuentes-Bayne H, Yin J, Asmus E, Ryder M, Morris JC, Hilger CR, Bible KC, Chintakuntlawar AV, Rao SN. Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. J Endocr Soc. 2022 May 01; 6(5):bvac044. Epub 2022 Mar 22.
    View PubMed
  5. Gao RW, Foote RL, Garces YI, Ma DJ, Neben-Wittich M, Routman DM, Patel SH, Ko SJ, McGee LA, Bible KC, Chintakuntlawar AV, Ryder M, Morris JC, Van Abel KM, Rivera M, Abraha F, Lester SC. Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy. Pract Radiat Oncol. 2022 Mar-Apr; 12 (2):113-119 Epub 2021 Oct 26
    View PubMed
  6. Bible KC. Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. AACE Clin Case Rep. 2021 Sep-Oct; 7 (5):334-335 Epub 2021 Mar 20
    View PubMed
  7. Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021 Jul 20; 39 (21):2359-2366 Epub 2021 May 07
    View PubMed
  8. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10; 39 (17):1856-1864 Epub 2021 Mar 22
    View PubMed
  9. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021 Mar; 31 (3):337-386
    View PubMed
  10. Bruce JY, Bible KC, Chintakuntlawar AV. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Thyroid 2021 Feb; 31 (2):332-333 Epub 2020 Aug 04
    View PubMed
  11. Bible KC, Menefee ME, Lin CC, Millward MJ, Maples WJ, Goh BC, Karlin NJ, Kane MA, Adkins DR, Molina JR, Donehower RC, Lim WT, Flynn PJ, Richardson RL, Traynor AM, Rubin J, LoRusso PM, Smallridge RC, Burton JK, Suman VJ, Kumar A, Voss JS, Rumilla KM, Kipp BR, Chintakuntlawar AV, Harris P, Erlichman C. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid. 2020 Sep; 30 (9):1254-1262 Epub 2020 July 29
    View PubMed
  12. Miller KC, Chintakuntlawar AV, Hilger C, Bancos I, Morris JC, Ryder M, Smith CY, Jenkins SM, Bible KC. Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. J Endocr Soc. 2020 Jul 1; 4 (7):bvaa069 Epub 2020 June 09
    View PubMed
  13. Iniguez-Ariza NM, Jasim S, Ryder MM, Chintakuntlawar AV, Morris JC, Hilger CR, Menefee ME, Smallridge RC, Karlin NJ, Alcaino C, Bible KC. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. J Clin Endocrinol Metab. 2020 Jul 1; 105 (7)
    View PubMed
  14. Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell M, Bible KC, Ryder M, Chintakuntlawar AV, Habra MA. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020 Jul; 8 (2)
    View PubMed
  15. Iniguez-Ariza NM, Bible KC, Clarke BL. Bone metastases in thyroid cancer. J Bone Oncol. 2020 Apr; 21:100282 Epub 2020 Feb 19
    View PubMed
  16. Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces Y, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC 3rd, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019 Nov; 29 (11):1615-1622
    View PubMed
  17. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Aug; 37 (4):755-762 Epub 2019 June 06
    View PubMed
  18. Chintakuntlawar AV, Foote RL, Kasperbauer JL, Bible KC. Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinol Metab Clin North Am. 2019 Mar; 48 (1):269-284
    View PubMed
  19. Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarzab B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simoes M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Fuhrer D. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019 Jan; 29 (1):7-26 Epub 2019 Jan 07
    View PubMed
  20. Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018 May; 66:64-73 Epub 2018 Apr 22
    View PubMed
  21. Iniguez-Ariza NM, Stan MN, Bible KC. Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. Endocrine. 2018 Jan; 59 (1):228-229 Epub 2017 Nov 01
    View PubMed
  22. Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, Hallemeier CL. External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2018 Jan-Mar; 3 (1):25-29 Epub 2017 Nov 22
    View PubMed
  23. Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Neben Wittich MA, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 Dec 1; 102 (12):4506-4514
    View PubMed
  24. Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd, Bible KC. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS. Endocr Pract. 2017 Aug 17;
    View PubMed
  25. Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017 Aug; 57 (2):220-225 Epub 2017 July 06
    View PubMed
  26. Iniguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid. 2017 Jul; 27 (7):923-927 Epub 2017 May 31
    View PubMed
  27. Jasim S, Nathan MA, Bible KC. "Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. Endocrine. 2017 Jul; 57 (1):187-188 Epub 2017 May 16
    View PubMed
  28. French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 Jun; 5 (6):469-481 Epub 2016 Oct 20
    View PubMed
  29. Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, Que FG, Nagorney DM, Young WF, Thompson GB. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Ann Surg Oncol. 2017 Jun; 24 (6):1546-1550 Epub 2017 Jan 05
    View PubMed
  30. Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017 Jun 01; 102(6):1943-1950.
    View PubMed
  31. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 Apr; 27 (4):481-483 Epub 2017 Feb 21
    View PubMed
  32. Jasim S, Chintakuntlawar A, Bible KC. Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma International Journal Of Endocrine Oncology. 2016 Nov; 3: (4)285-9.
  33. Bible KC, Ryder M. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol 2016 Sep; 17 (9):1181-3 Epub 2016 July 23
    View PubMed
  34. Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016 Jul; 13 (7):403-16 Epub 2016 Mar 01
    View PubMed
  35. Spitzweg C, Morris JC, Bible KC. New drugs for medullary thyroid cancer: new promises? Endocr Relat Cancer. 2016 Jun; 23: (6)R287-97.
    View PubMed
  36. Bible KC, Chintakuntlawar AV, Ryder M. Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. J Oncol Pract 2016 Jun; 12 (6):521-2
    View PubMed
  37. Rosenthal MS, Angelos P, Bible K, Fassler CA, Finder S, Greene LW, Tulchinsky M. Informed consent for low-risk thyroid cancer International Journal Of Endocrine Oncology. 2016 May; 3: (2)131-42.
  38. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26 (1):1-133
    View PubMed
  39. Bible KC, Cote GJ, Demeure MJ, Elisei R, Jhiang S, Ringel MD, International Thyroid Oncology Group Correlative Science Committee. Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. J Clin Endocrinol Metab. 2015 Dec; 100 (12):4387-95 Epub 2015 Sept 29
    View PubMed
  40. Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, Evans DB, Grubbs EG, Bible KC, Young WF, Perrier ND, Que FG, Nagorney DM, Lee JE, Thompson GB. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015 Jan; 22 (1):146-51 Epub 2014 Aug 05
    View PubMed
  41. Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014 Oct; 2 (10):830-42 Epub 2014 June 02
    View PubMed
  42. Isham CR, Netzel BC, Bossou AR, Milosevic D, Cradic KW, Grebe SK, Bible KC. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. J Clin Endocrinol Metab. 2014 Jun; 99 (6):E936-43 Epub 2014 Mar 14
    View PubMed
  43. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May; 99 (5):1687-93 Epub 2014 Feb 25
    View PubMed
  44. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13
    View PubMed
  45. Dy BM, Wise KB, Richards ML, Young WF Jr, Grant CS, Bible KC, Rosedahl J, Harmsen WS, Farley DR, Thompson GB. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013 Dec; 154(6):1292-9; discussion 1299.
    View PubMed
  46. Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31 (5):1201-6 Epub 2013 July 26
    View PubMed
  47. Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013 Jun; 98 (6):2392-400 Epub 2013 Apr 15
    View PubMed
  48. Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013 Jan 2; 5 (166):166ra3
    View PubMed
  49. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM, American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov; 22 (11):1104-39
    View PubMed
  50. Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C, Mayo Phase 2 Consortium (P2C)//North Central Cancer Treatment Group (NCCTG). A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol. 2012 Oct; 127 (1):55-62 Epub 2012 June 01
    View PubMed
  51. Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C, Mayo Phase 2 Consortium//Mayo Clinic Endocrine Malignances Disease Oriented Group. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012 Sep; 97 (9):3179-84 Epub 2012 July 06
    View PubMed
  52. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May; 8 (3 Suppl):e1s-5s
    View PubMed
  53. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. Am J Manag Care. 2012 May 1; 18 (5):e162-7 Epub 2012 May 01
    View PubMed
  54. Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC. The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. Br J Cancer. 2012 Jan 17; 106 (2):314-23 Epub 2011 Dec 20
    View PubMed
  55. Menefee ME, Smallridge RC, Bible KC. Systemic therapeutic approaches to advanced thyroid cancers. Am Soc Clin Oncol Educ Book. 2012; 389-92
    View PubMed
  56. Reddi HV, Madde P, Cohen YC, Bangio L, Breitbart E, Harats D, Bible KC, Eberhardt NL. Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. Genes Cancer. 2011 Oct; 2 (10):993-5
    View PubMed
  57. Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011 Oct; 20(10):1357-75.
    View PubMed
  58. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011 Jan; 21 (1):25-30 Epub 2010 Dec 16
    View PubMed
  59. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group//Mayo Clinic Cancer Center//Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct; 11 (10):962-72 Epub 2010 Sept 17
    View PubMed
  60. Tibodeau JD, Isham CR, Bible KC. Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductase. Antioxid Redox Signal. 2010 Oct 1; 13 (7):987-97
    View PubMed
  61. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol. 2010 Jul 1; 28 (19):e312-3 Epub 2010 June 01
    View PubMed
  62. Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal. 2009 May; 11 (5):1097-106
    View PubMed
  63. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs. 2008 Feb; 26(1):59-65. Epub 2007 Oct 16.
    View PubMed
  64. Pizarro GO, Zhou XC, Koch A, Gharib M, Raval S, Bible K, Jones MB. Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse. Int J Cancer. 2007 Jun 1; 120 (11):2339-43
    View PubMed
  65. Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem. 2007 Mar 23; 282(12):8860-72. Epub 2007 Jan 09.
    View PubMed
  66. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood. 2007 Mar 15; 109 (6):2579-88 Epub 2006 Nov 07
    View PubMed
  67. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 2006 Jul; 116 (7):1994-2004 Epub 2006 June 08
    View PubMed
  68. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica. 2006 Mar; 91(3):390-3. Epub 2006 Feb 17.
    View PubMed
  69. Lee YK, Isham CR, Kaufman SH, Bible KC. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther. 2006 Jan; 5 (1):138-48
    View PubMed
  70. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005 Dec 1; 11(23):8403-12.
    View PubMed
  71. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005 Aug 15; 11 (16):5935-41
    View PubMed
  72. Fatima J, Gipson JC, Farnell MB, Bible KC. Is this really a duodenal adenocarcinoma? What is this mass and why should a surgeon be involved? Contemp Surg. 2005 Aug; 61(8):393-397.
  73. Boerner SA, Tourne ME, Kaufmann SH, Bible KC. Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer. 2001 May 18; 84 (10):1391-6
    View PubMed
  74. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001 May 15; 61 (10):4258-65
    View PubMed
  75. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001 Jan 15; 61 (2):739-48
    View PubMed
  76. Bible KC, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH. Flavopiridol binds to duplex DNA. Cancer Res. 2000 May 1; 60 (9):2419-28
    View PubMed
  77. Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res. 2000 Feb; 6 (2):661-70
    View PubMed
  78. Mesner PW Jr, Bible KC, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH. Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile. J Biol Chem. 1999 Aug 6; 274 (32):22635-45
    View PubMed
  79. Bible KC, Boerner SA, Kaufmann SH. A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid. Anal Biochem. 1999 Feb 1; 267(1):217-21.
    View PubMed
  80. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997 Aug 15; 57(16):3375-80.
    View PubMed
  81. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996 Nov 1; 56 (21):4856-61
    View PubMed
  82. Sings HL, Bible KC, Rinehart KL. Acyl tunichlorins: a new class of nickel chlorins isolated from the Caribbean tunicate Trididemnum solidum. Proc Natl Acad Sci U S A. 1996 Oct 1; 93(20):10560-5.
    View PubMed
  83. Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996 May; 93 (2):406-8
    View PubMed
  84. Bible KC, Buytendorp M, Zierath PD, Rinehart KL. Tunichlorin: a nickel chlorin isolated from the Caribbean tunicate Trididemnum solidum. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4582-6.
    View PubMed
  85. Rinehart KL, Kishore V, Bible KC, Sakai R, Sullins DW, Li KM. Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum. J Nat Prod. 1988 Jan-Feb; 51(1):1-21.
    View PubMed
  86. Bible KC, Nelson RA, et al. Renal function in hospitalized patients receiving intravenous infusions of amino acids. Carle Sel Pap. 1986 Fall; 38:27-33.
  87. Bible KC, Hatfield AK, Lansford CL, Kammer BA. Gastric ulceration as a complication of hepatic artery infusion chemotherapy. South Med J. 1986 Jun; 79(6):755-7.
    View PubMed
  88. Witte DL, Persoon TJ, Bible K, Routh JI. Choice of reference sera for measurement of effective thyroxine ratio. J Nucl Med Technol. 1978; 6:69-72.